BTC $62,463.25 -0.81%
ETH $1,777.97 -0.44%
BNB $569.09 -0.08%
XRP $1.06 -1.16%
SOL $74.88 -1.98%
TRX $0.3245 -1.50%
DOGE $0.0720 -0.44%
ADA $0.1586 -0.97%
BCH $234.66 -0.96%
LINK $7.91 -0.71%
HYPE $63.51 -2.71%
AAVE $95.64 +1.11%
SUI $0.7300 -0.24%
XLM $0.1786 -2.69%
ZEC $504.52 -3.05%
BTC $62,463.25 -0.81%
ETH $1,777.97 -0.44%
BNB $569.09 -0.08%
XRP $1.06 -1.16%
SOL $74.88 -1.98%
TRX $0.3245 -1.50%
DOGE $0.0720 -0.44%
ADA $0.1586 -0.97%
BCH $234.66 -0.96%
LINK $7.91 -0.71%
HYPE $63.51 -2.71%
AAVE $95.64 +1.11%
SUI $0.7300 -0.24%
XLM $0.1786 -2.69%
ZEC $504.52 -3.05%

The US-listed company LIXTE has invested $2.6 million in cryptocurrency, increasing its allocation ratio to 50%

2025-09-11 08:26:51
Collection

ChainCatcher news, Nasdaq-listed company LIXTE Biotechnology Holdings (stock codes: LIXT and LIXTW) announced on September 10 that it has purchased 10.5 Bitcoin and 300 Ethereum for a total value of approximately $2.6 million as part of its diversification strategy.

According to the announcement, cryptocurrencies currently account for 43.6% of LIXTE's capital holdings, and the company's board has approved increasing the allocation of cryptocurrency to 50%. LIXTE Chairman and CEO Geordan Pursglove stated that this move aims to build a balanced and flexible digital asset strategy, enhancing the company's adaptability and long-term growth potential in the digital economy. Previously, it was reported that the U.S. listed biotech company LIXTE plans to allocate up to 25% of its capital reserves to digital assets such as Bitcoin.

app_icon
ChainCatcher Building the Web3 world with innovations.